These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
139 related items for PubMed ID: 15571267
1. Genetic determinants of the pre- and post-azathioprine therapy thiopurine methyltransferase activity phenotype. Arenas M, Duley JA, Ansari A, Shobowale-Bakre EA, Fairbanks L, Soon SY, Sanderson J, Marinaki AM. Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1403-5. PubMed ID: 15571267 [Abstract] [Full Text] [Related]
2. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, Vinner E, Marez D, Lo Guidice JM, Chevalier D, Brique S, Motte K, Colombel JF, Turck D, Noel C, Flipo RM, Pol A, Lhermitte M, Lafitte JJ, Libersa C, Broly F. Br J Pharmacol; 1998 Oct; 125(4):879-87. PubMed ID: 9831928 [Abstract] [Full Text] [Related]
3. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Snow JL, Gibson LE. Arch Dermatol; 1995 Feb; 131(2):193-7. PubMed ID: 7857117 [Abstract] [Full Text] [Related]
4. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Spire-Vayron de la Moureyre C, Debuysère H, Fazio F, Sergent E, Bernard C, Sabbagh N, Marez D, Lo Guidice JM, D'halluin JC, Broly F. Pharmacogenetics; 1999 Apr; 9(2):189-98. PubMed ID: 10376766 [Abstract] [Full Text] [Related]
5. The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation. Fabre MA, Jones DC, Bunce M, Morris PJ, Friend PJ, Welsh KI, Marshall SE. Transpl Int; 2004 Oct; 17(9):531-9. PubMed ID: 15349717 [Abstract] [Full Text] [Related]
6. Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine. Zhu Q, Cao Q. Chin Med J (Engl); 2012 Oct; 125(20):3665-70. PubMed ID: 23075721 [Abstract] [Full Text] [Related]
8. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Cao Q, Zhu Q, Shang Y, Gao M, Si J. Digestion; 2009 Aug; 79(1):58-63. PubMed ID: 19252404 [Abstract] [Full Text] [Related]
9. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Clunie GP, Lennard L. Rheumatology (Oxford); 2004 Jan; 43(1):13-8. PubMed ID: 14566029 [Abstract] [Full Text] [Related]
11. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. Coulthard SA, Matheson EC, Hall AG, Hogarth LA. Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1385-91. PubMed ID: 15571264 [Abstract] [Full Text] [Related]
12. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Bruce I, Payne K. J Clin Pharm Ther; 2007 Apr; 32(2):187-95. PubMed ID: 17381669 [Abstract] [Full Text] [Related]
13. [Association between metabolic enzyme genotype of azathioprine and drug tolerance in patients with rheumatic diseases]. Zhan ZP, Liang LQ, Yang XY, Wang YX, Huang M, Li H. Zhonghua Yi Xue Za Zhi; 2007 Jul 03; 87(25):1734-7. PubMed ID: 17919375 [Abstract] [Full Text] [Related]
14. High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease. Larussa T, Suraci E, Lentini M, Nazionale I, Gallo L, Abenavoli L, Imeneo M, Costanzo FS, Cuda G, Luzza F. Eur J Intern Med; 2012 Apr 03; 23(3):273-7. PubMed ID: 22385887 [Abstract] [Full Text] [Related]
15. Mistaken identity: misclassification of TPMT phenotype following blood transfusion. Cheung ST, Allan RN. Eur J Gastroenterol Hepatol; 2003 Nov 03; 15(11):1245-7. PubMed ID: 14560161 [Abstract] [Full Text] [Related]
16. Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism. Boonsrirat U, Angsuthum S, Vannaprasaht S, Kongpunvijit J, Hirankarn N, Tassaneeyakul W, Avihingsanon Y. Lupus; 2008 Feb 03; 17(2):132-4. PubMed ID: 18250137 [Abstract] [Full Text] [Related]
17. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM. Hepatogastroenterology; 2006 Feb 03; 53(69):399-404. PubMed ID: 16795981 [Abstract] [Full Text] [Related]
18. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Seidman EG. Rev Gastroenterol Disord; 2003 Feb 03; 3 Suppl 1():S30-8. PubMed ID: 12684587 [Abstract] [Full Text] [Related]
19. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M. Ther Drug Monit; 2007 Feb 03; 29(1):1-5. PubMed ID: 17304143 [Abstract] [Full Text] [Related]
20. Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Marinaki AM, Arenas M, Khan ZH, Lewis CM, Shobowale-Bakre el-M, Escuredo E, Fairbanks LD, Mayberry JF, Wicks AC, Ansari A, Sanderson J, Duley JA. Pharmacogenetics; 2003 Feb 03; 13(2):97-105. PubMed ID: 12563179 [Abstract] [Full Text] [Related] Page: [Next] [New Search]